NCT05635461View on ClinicalTrials.gov

Relative Bioavailability and Food Effect Study of CVN424

PHASE1CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

October 9, 2022

Primary Completion Date

November 11, 2022

Study Completion Date

November 21, 2022

Conditions

Parkinson's Disease

Interventions

DRUG

CVN424

150 mg of either tablet or suspension formulation

Trial Locations (1)

85283

Celerion, Tempe

All Listed Sponsors

lead

Cerevance Beta, Inc.

INDUSTRY